Topic summary

Analytical identity of BPC-157: a 15-mer with a simple mass

Compounds › Repair & healing peptides BPC-157 observational data needs a source preprint TB-500

This is a generated summary. It shows the 5 most-liked posts from a topic of 8, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

m.rasmussenTL2 Moderator27 Jul 2025#1

Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did.

Comparing SURMOUNT-OSA (N Engl J Med, 2024) with STEP 2 (Lancet, 2021) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

18 likes 12mo

weekly_pinTL2Regular26 Aug 2025#4

formulary_notes, post #2: the opening post is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

22 likes in reply to #2 11mo

i.ilungaTL2 Moderator2 Sep 2025#5

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

6 likes 11mo

r.weissTL2 Moderator16 Sep 2025#7

i.ilunga, post #5: Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons — bioavailability, off-target effects, metabolism, clearance, or simply that the mechanism does not do what the theory predicts in a living system. Plausibility is necessary for hope but not sufficient for evidence.

30 likes in reply to #5 10mo

i.aranda_esTL2Translator · ES23 Sep 2025#8

weekly_pin, post #4: The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones. Go to post

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

15 likes in reply to #4 10mo

Read the full topic (8 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
What would change my mind about repair peptides: a specific answer Compounds › Repair & healing peptides TB-500 needs a source preprint Under review What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please…	+26	30	1.1k	23h
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Compounds › Repair & healing peptides observational data TB-500 BPC-157 preprint Solved Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…	+50	55	7.8k	2d
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+23	27	7.7k	15mo
Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides preprint BPC-157 TB-500 needs a source Solved Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…	+40	45	3.4k	21h
Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides BPC-157 observational data preprint TB-500 Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…	+20	24	47k	4mo

Related topics — sharing the tags BPC-157, observational data, needs a source

Topic	Participants	Replies	Views	Activity
Naming conventions for research peptides and the confusion they cause — one year on Compounds › Other compounds research use only mislabelling needs a source Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…	+1	5	181	2y
Why catalogue breadth is not evidence of anything Compounds › Other compounds research use only needs a source custom synthesis Under review Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…		2	38k	2d
Tracking a preprint to publication: a worked example — the long version Evidence › Preprints risk of bias preprint effect size Posting this under the heading it deserves: Tracking a preprint to publication: a worked example — the long version Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 2 (…	+38	47	560	22mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…	+100	108	1.3k	8mo
Coming back to: A critique that turned out to be unfair, retracted by its author Evidence › Study critique disputed observational data effect size confounding Closed A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not…		2	1.3k	14mo